1	
2	Title Page
3	Predictors of survival in patients with ischemic stroke and active cancer: A prospective,
4	multicenter, observational study
5	
6	Authors' names and affiliations:
7	Yasufumi Gon, MD, PhD ¹ ; Manabu Sakaguchi, MD, PhD ^{1,2} ; Hiroshi Yamagami, MD, PhD ³ ;
8	Soichiro Abe, MD ⁴ ; Hiroyuki Hashimoto, MD, PhD ⁵ ; Nobuyuki Ohara, MD ⁶ ; Daisuke
9	Takahashi, MD ⁷ ; Yuko Abe, MD, PhD ⁸ ; Tsutomu Takahashi, MD, PhD ⁹ ; Takaya Kitano, MD,
10	PhD ¹ ; Shuhei Okazaki, MD, PhD ¹ ; Kenichi Todo, MD, PhD ¹ ; Tsutomu Sasaki, MD, PhD ¹ ;
11	Satoshi Hattori, PhD ¹⁰ ; and Hideki Mochizuki, MD, PhD ¹ ; on behalf of the SCAN Study
12	Investigators
13	
14	Institutional Information
15	¹ Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
16	² Department of Neurology, Osaka General Medical Center, Osaka, Japan
17	³ Department of Neurology, National Hospital Organization Osaka National Hospital, Osaka,
18	Japan
19	⁴ Department of Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan
20	⁵ Department of Neurology, Osaka Rosai Hospital, Osaka, Japan
21	⁶ Department of Neurology, Kobe City Medical Center General Hospital, Hyogo, Japan
22	⁷ Department of Neurology, National Hospital Organization Osaka Minami Medical Center,
23	Osaka, Japan
24	⁸ Department of Neurology, Yodogawa Christian Hospital, Osaka, Japan
25	⁹ Department of Neurology, Hoshigaoka Medical Center, Osaka, Japan

PAGE 2

- ¹⁰ Department of Integrated Medicine, Biomedical Statistics, Osaka University of Graduate
- 27 School of Medicine, Osaka, Japan

28

- 29 Short title: Prognosis in ischemic stroke with active cancer
- **30** Corresponding author:
- 31 Yasufumi Gon, MD, PhD.
- 32 Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka,
- 33 Suita, Osaka 565-0871, Japan.
- 34 Phone: +81-6-6879-3571; Fax: +81-6-6879-3579
- 35 E-mail address: gon@neurol.med.osaka-u.ac.jp
- **36 Total word count:** 6,520

37

PAGE 3

38 Abstract

39 Background: Patients with ischemic stroke and active cancer have a poor prognosis; however,

40 supporting evidence remains limited.

Methods: We conducted a prospective, multicenter, observational study in Japan including patients with acute ischemic stroke and active cancer to investigate the prognostic factors. We followed up the patients for 1 year after stroke onset. The patients were divided into two groups according to cryptogenic stroke and known etiologies (small vessel occlusion, large artery atherosclerosis, cardioembolism, other determined etiology) and survival was compared. The hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality were calculated using Cox regression models.

48 **Results:** We identified 135 eligible patients (39% women; median age, 75 years). Of these, 49 51% had distant metastasis. A total of 65 (48%) and 70 (52%) patients had cryptogenic stroke 50 and known etiologies, respectively. Patients with cryptogenic stroke had significantly shorter 51 survival than those with known etiologies (HR [95% CI], 3.11 [1.82–5.25]). The multivariate 52 Cox regression analysis revealed that distant metastasis, plasma D-dimer levels, deep venous 53 thrombosis and/or pulmonary embolism complications at stroke onset were independent 54 predictors of mortality after adjusting for potential confounders. Cryptogenic stroke was 55 associated with prognosis in univariate analysis but not significant in multivariate analysis. The 56 plasma D-dimer levels stratified the prognosis of patients with ischemic stroke and active 57 cancer.

58 Conclusions: The prognosis of patients with acute ischemic stroke and active cancer varies 59 considerably depending on stroke mechanism, distant metastasis, and coagulation 60 abnormalities. Coagulation abnormalities are crucial in determining the prognosis of such 61 patients.

62 Key Words: ischemic stroke, active cancer, D-dimer, cryptogenic stroke, distant metastasis

00 What 19 110 W .

64	•	We conducted a prospective, multicenter, observational study in Japan to determine
65		the prognostic survival factors in patients with acute ischemic stroke and active
66		cancer.
67	•	Distant metastasis, plasma D-dimer levels, deep venous thrombosis and/or
68		pulmonary embolism were independent predictors of mortality after adjusting for
69		potential confounders.
70	•	Patients with known stroke etiologies and mild coagulation abnormalities had a
71		favorable prognosis, whereas those with cryptogenic stroke and severe coagulation
72		abnormalities had a poor outcome.
73		
74	Wh	at Are the Clinical Implications?
75	•	The prognosis of patients with acute ischemic stroke and active cancer varies
76		considerably depending on stroke mechanism, distant metastasis, and coagulation
77		abnormalities.
78	•	Patients with known stroke etiologies and mild coagulation abnormalities often have
79		a favorable prognosis; therefore, we should not stop stroke therapy because of active
80		cancer.
81	•	Patients with cryptogenic stroke and severe coagulation abnormalities often have
82		poor outcomes; consequently, we should thoroughly discuss with the oncologist to
83		determine a treatment plan.
84		

PAGE 5

85 Non-standard Abbreviations and Acronyms

86	HR	Hazard ratio
87	CI	Confidence interval
88	SCAN	Ischemic Stroke in Patients with Cancer and Neoplasia
89	NIHSS	National Institute of Health Stroke Scale
90	DVT	Deep venous thrombosis
91	PE	Pulmonary embolism
92	mRS	modified Rankin Scale
93	rt-PA	Recombinant-tissue plasminogen activator
94	hsCRP	High-sensitivity C-reactive protein
95	TOAST	Trial of Org 10172 in Acute Stroke Treatment
96	IQR	Interquartile range
97	AIC	Akaike's information criterion

PAGE 6

98

99 Introduction

Patients with cancer are at increased risk of cerebrovascular diseases [1,2]. Stroke is a
significant concern for patients with cancer since it can interrupt cancer treatments and worsen
survival outcomes [1–5]. Management of cancer and stroke is an important aspect of clinical
practice.

104 Patients with ischemic stroke and active cancer experience poor survival outcomes. 105 Lee et al. investigated 268 patients with ischemic stroke and active cancer using data from the 106 OASIS-Cancer study and reported a median survival of 109 days [6]. Navi et al. analyzed 263 107 patients with ischemic stroke and active cancer and found a median survival of 84 days for 230 108 patients with complete follow-up [7]. Shin et al. investigated 93 patients with cryptogenic 109 stroke and active cancer and showed a median survival of 62 days [8]. Other studies compared 110 ischemic stroke outcomes in patients with and without active cancer, suggesting that ischemic 111 stroke patients with active cancer have poorer outcomes than those without [9-14]. Overall, 112 patients with ischemic stroke and active cancer are known to have poor survival outcomes. 113 However, most of these studies are retrospective [7–12,14], and limited data are available 114 concerning prospective studies [6,13].

115 The prognostic indicators of survival are poorly understood in patients with ischemic 116 stroke and active cancer [15]. Previous studies have suggested that distant metastasis, diabetes 117 mellitus, plasma D-dimer levels, cryptogenic stroke, and pre-stroke modified Rankin Scale 118 (mRS) were associated with mortality [8,16-18]. Among these factors, cryptogenic stroke is a 119 common ischemic stroke subtype in patients with active cancer [16,19–21]. It is also known 120 that plasma D-dimer levels are high in cancer patients with cryptogenic stroke [19,20]. Thus, 121 the fact that both cryptogenic stroke and plasma D-dimer levels predict prognosis may reflect 122 underlying coagulation abnormalities. However, the relationship between cryptogenic stroke

PAGE 7

123	and	plasma	D-dimer	levels	in	predicting	cancer-related	stroke	prognosis	has	been
124	unde	erexplored	d.								

125	Based on this background, we conducted a prospective, multicenter, observational
126	study of patients with ischemic stroke and with cancer (ischemic Stroke in patients with
127	CAncer and Neoplasia [SCAN]) in Japan. The SCAN study was designed to assess the clinical
128	characteristics of cancer-related strokes. In the present study, we analyzed the survival of
129	patients with acute ischemic stroke and active cancer according to the stroke subtype, using
130	data from the SCAN study.
131	

```
132 Methods
```

- 133 Data Availability
- 134 The data that support the findings of this study are available from the corresponding author135 upon reasonable request.

136 Standard Protocol Approvals, Registrations, and Patient Consents

137 This study complied with the Declaration of Helsinki for investigations involving humans and

138 was approved by the Institutional Review Board of Osaka University Hospital (approval

139 number: 15346-10). Written informed consent was obtained from all study patients.

140 Study Design and Population

141 The SCAN study is a prospective, multicenter, observational study conducted at nine hospitals 142 in Japan, between June 2016, and December 2021 (Osaka University Hospital, Osaka General 143 Medical Center, National Cerebral and Cardiovascular Center Hospital, National Hospital 144 Organization Osaka National Hospital, Osaka Rosai Hospital, Kobe City Medical Center 145 General Hospital, National Hospital Organization Osaka Minami Medical Center, Yodogawa 146 Christian Hospital, and Hoshigaoka Medical Center). All hospitals included the SCAN study 147 function as regional stroke centers. The inclusion criteria were as follows: (1) acute ischemic

PAGE 8

stroke within 14 days following symptom onset, (2) age ≥ 20 years, and (3) active cancer at stroke onset. Active cancer was defined as a diagnosis of cancer, either treated in the last six months before admission or untreated, or metastatic disease. The SCAN study aimed to enroll approximately 250 patients over a 5-year study period, with a 1-year follow-up from the enrollment date to investigate the prognosis of patients with acute ischemic stroke and active cancer.

154 Clinical Variables

155 The following baseline variables were obtained from the SCAN database: age, sex, 156 hypertension, dyslipidemia, diabetes mellitus, smoking, atrial fibrillation, past stroke, time 157 from symptom onset to admission, antithrombotic (antiplatelet and/or anticoagulant) 158 medication before and after stroke onset, stroke subtype, National Institute of Health Stroke 159 Scale (NIHSS), pre-stroke mRS, deep venous thrombosis and/or pulmonary embolism 160 (DVT/PE) complications at stroke onset, infarct pattern of brain imaging, use of 161 recombinant-tissue plasminogen activator (rt-PA), mechanical thrombectomy, and 162 cancer-related data including cancer type, distant metastasis, adenocarcinoma, and cancer 163 treatment (cancer surgery, chemotherapy, and radiotherapy). We also collected the recurrent 164 stroke and major bleeding information during the observation period. Stroke recurrence was 165 defined as a new neurological deficit together with corresponding evidence of acute ischemia 166 or hematoma on brain imaging (computed tomography and/or magnetic resonance imaging). Major bleeding was defined as clinically overt bleeding that was accompanied by one or more 167 168 of the following: a decrease in hemoglobin levels of at least 2 g/dL or the requirement of a 169 transfusion with at least 2 units of packed red blood cells; symptomatic bleeding requiring 170 immediate treatment that occurred at a critical site, such as intracranial, intraocular, intraspinal, 171 intra-articular, intramuscular with compartment syndrome, pericardial or retroperitoneal; or 172 bleeding that was fatal. Blood samples were collected immediately after admission before any

PAGE 9

treatment started, and plasma D-dimer and high sensitivity C-reactive protein (hsCRP) levelswere quantified.

175 Subtypes of ischemic stroke were classified according to the Trial of Org 10172 in 176 Acute Stroke Treatment (TOAST) criteria: small vessel occlusion, large artery atherosclerosis, 177 cardioembolism, other determined etiology, and stroke of undetermined etiology [24]. All the 178 patients underwent blood tests, 24-hour electrocardiographic monitoring at least 7 days after 179 admission, carotid ultrasonography, and brain imaging (computed tomography and/or 180 magnetic resonance imaging). Transthoracic and transesophageal echocardiography was 181 performed as necessary. We determined that patients had a cryptogenic stroke if the cause 182 could not be determined with any degree of confidence [24]. Patients with no apparent cause of 183 ischemic stroke other than malignancies were categorized as having a cryptogenic stroke.

184 Follow Up Duration and Outcomes

185 The observation period was one year after the diagnosis of ischemic stroke. All the patients 186 were followed-up via telephone or outpatient visits. The incidence of death, stroke recurrence, 187 and major bleeding were investigated.

188 Statistical Analyses

189 Descriptive statistics were presented using the median and interquartile range (IQR) for190 continuous variables and as proportions and counts for categorical variables.

First, we summarized the baseline characteristics of the cohort. Next, we divided the patients into two groups based on the cryptogenic stroke and known etiologies (small vessel occlusion, large artery atherosclerosis, cardioembolism, and other determined etiology) and verified the survival rates against previously reported findings [7,8]. Survival rates for all-cause mortality were calculated using the Kaplan-Meier method. Finally, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality using univariate and multivariate Cox proportional hazard models. Based on clinical experience, we selected the

PAGE 10

198 following variables as potential confounders: age, sex, hypertension, dyslipidemia, diabetes 199 mellitus, atrial fibrillation, pre-mRS ≤ 2 , NIHSS score, distant metastasis, cryptogenic stroke, 200 recurrent stroke, major bleeding, past stroke, pre-stroke antithrombotic use, pre-stroke cancer 201 treatment status, DVT/PE complications at stroke onset, and plasma D-dimer levels. In the 202 multivariate analysis, we developed two models to identify independent predictors of 203 prognosis: the forced entry method for all potential confounders (Model 1) and the stepwise 204 selection method to address the possibility of multicollinearity (Model 2). Since we were 205 interested in cryptogenic stroke as a prognostic marker for survival, the stroke mechanism was 206 forced to be included in Model 2, and other factors were selected using a stepwise procedure 207 with Akaike's information criterion (AIC) [25]. Recurrent stroke and major bleeding were 208 treated as time-varying variables. Plasma D-dimer levels were divided into quartiles, and the 209 first quartile was used as a reference.

The cumulative incidence of recurrent stroke and major bleeding during the observation period was calculated using the Fine and Gray model [26], with death as a competing risk. The incidence was compared with the use of antithrombotic medications.

213 Statistical analysis was performed using the R software (https://cran.r-project.org/). 214 The level of significance was set at P < 0.05. All tests were two tailed.

215

216 **Results**

217 Study Population and Characteristics of the Patients according to Stroke Subtypes

A total of 135 patients were included in the analysis. **Table 1** lists the cancer types of the included patients and whether distant metastasis were present. The most common types of

- 220 cancers were lung (16%), colorectal (14%), pancreatic (13%), prostate (9%), and gastric (8%)
- 221 cancers. Distant metastasis was observed in 51% (n = 69) of the patients.

Table 2 summarizes the characteristics of the study cohort. Overall, the median (IQR)

PAGE 11

223 age was 75 (69–81) years, and 39% of the patients were women. The median (IQR) time from 224 symptom onset to admission was 0 (0-2) days. Antithrombotic medications were used in 30% 225 of the patients before stroke and 82% after ischemic stroke (breakdown of antithrombotic 226 medications after stroke is shown in Table S1). Cryptogenic stroke was the most common 227 stroke subtype (48%), and other determined etiology was the least common (7%). The median 228 NIHSS (IQR) score was 4 (2-10). Ten patients (7%) had DVT/PE at stroke onset. 229 Thrombolysis by rt-PA and mechanical thrombectomy were performed in 7% and 10% of the 230 patients, respectively. The frequency of the patients undergoing cancer treatment was 76%, and 231 approximately half of them received chemotherapy. The median (IQR) levels of plasma 232 D-dimer and hsCRP were 3.65 $(1.41-11.72) \mu g/mL$ and 1.06 (0.18-3.95) mg/dL, respectively. 233 Compared to the patients with known etiologies, those with cryptogenic stroke were 234 more frequent in women, infarcts in multiple vascular territories, DVT/PE complications at 235 stroke onset, and distant metastasis, while less frequent in those with hypertension, atrial 236 fibrillation, past stroke, cancer treatment, and antiplatelet medication after stroke. Pre-stroke 237 functional status was worse in patients with cryptogenic stroke compared with those with 238 known etiologies (pre-mRS [IQR], 1 [0–3] vs. 0 [0–2], P = 0.039). The cryptogenic stoke 239 group had higher plasma D-dimer levels (10.35 [3.59–22.38] µg/mL vs. 1.76 [0.83–3.73] 240 μ g/mL, P < 0.001) and serum hsCRP levels (2.50 [0.44–5.97] mg/dL vs. 0.44 [0.12–2.56] 241 mg/dL, P < 0.001) compared to the known etiologies group.

242 Survival Outcomes and Prognostic Factors

Among the 135 patients enrolled, 133 had completed 1-year follow-up: two cases were censored at the end of the follow-up. The median (IQR) survival time for all patients was 365 (71–365) days. The survival rates (95% CI) at 3 and 12 months were 70 (62–78) % and 54 (46– 63) %, respectively. **Figure 1** shows the difference in survival rates between patients with cryptogenic stroke and known etiologies. Patients with cryptogenic stroke had shorter survival

PAGE 12

times than those with known etiologies (113 [43–365] days vs. 365 [204–365] days, P < 0.001;
HR [95% CI], 3.11 [1.82–5.25]).

250 Table 3 summarizes the Cox regression analyses. Univariate analysis revealed that 251 hypertension, atrial fibrillation, cryptogenic stroke, NIHSS score, DVT/PE complications at 252 stroke onset, distant metastasis, pre-stroke cancer treatment, recurrent stroke, and plasma 253 D-dimer levels were associated with survival outcomes. Multivariate analysis revealed that 254 DVT/PE complications at stroke onset and distant metastasis were significantly associated 255 with mortality in Model 1, the forced entry method for all potential confounders. In Model 2, 256 which selected variables using a stepwise procedure with AIC, DVT/PE complications at 257 stroke onset, distant metastasis, and plasma D-dimer levels were independent predictors of 258 prognosis. Cryptogenic stroke was associated with outcomes in univariate analysis but not 259 significant in multivariate analysis. These results suggest a strong relationship between cancer 260 progression, the degree of cancer-associated coagulopathy, and prognosis in patients with 261 ischemic stroke and active cancer.

262 Recurrent Stroke and Major Bleeding during the Observation Period

263 The cumulative incidence (95% CI) of recurrent stroke and major bleeding were 10 264 (5-15) % and 7 (3-12) %, respectively. Figure 2 shows the cumulative incidence of recurrent 265 stroke between the groups treated with and without antithrombotic medications after stroke. 266 The recurrent stroke was significantly lower in the group with antithrombotic agents than in 267 those without (7 [3-13] % vs. 21 [8-39] %, P = 0.04; HR [95% CI], 0.32 [0.11-0.97]). Figure 268 **3** shows the cumulative incidence of major bleeding between the groups. There was no 269 significant difference in major bleeding between the groups treated with and without 270 antithrombotic medications (8 [1–23] % vs. 6 [3–12] %, P = 0.86; HR [95% CI], 0.87 [0.18– 271 4.10]).

272 Survival Estimate Using Distant Metastatic Status, Stroke Subtype, and Plasma D-Dimer

PAGE 13

273 Levels

Our analysis revealed that stroke mechanism, coagulation abnormalities, and cancer progression contributed to predict the prognosis in patients with ischemic stroke and active cancer. To investigate the usefulness of plasma D-dimer levels, we examined the relationship between plasma D-dimer levels and survival outcomes, stratified by distant metastasis and stroke subtypes.

Figure 4 shows the distribution of the plasma D-dimer levels according to distant metastasis and cryptogenic stroke status. Plasma D-dimer levels were significantly higher in patients with metastasis than those with non-metastasis (Figure 4A, 8.51 [2.20–20.72] μ g/mL vs. 1.91 [0.79–6.71] μ g/mL, *P* < 0.001). As already shown in Table 2, patients with cryptogenic stroke had significantly higher plasma D-dimer levels than those with known etiologies (Figure 4B, 10.35 [3.59–22.38] μ g/mL vs. 1.76 [0.83–3.73] μ g/mL, *P* < 0.001).

285 Figure 5A shows the survival curves based on distant metastatic status and median 286 plasma D-dimer levels of each group. As shown in Figure 4A, the median plasma D-dimer 287 levels were 1.91 μ g/mL for the group with non-metastasis and 8.51 μ g/mL for the group with 288 metastasis; therefore, we divided the patients into four groups based on distant metastasis 289 status and median plasma D-dimer levels. The 1-year survival rates were 12% in patients with 290 distant metastasis and high plasma D-dimer levels and 84% in patients with non-metastasis and 291 low plasma D-dimer levels. Figure 5B shows the survival curves based on stroke subtype and 292 median plasma D-dimer levels of each group. As shown in Figure 4B, the median plasma 293 D-dimer levels were 1.76 μ g/mL for the known etiologies group and 10.35 μ g/mL for the 294 cryptogenic stroke group; therefore, we divided the patients into four groups based on the 295 stroke subtype and median plasma D-dimer levels. The 1-year survival rates were 20% in 296 patients with cryptogenic stroke and high plasma D-dimer levels and 81% in patients with 297 known stroke etiologies and low plasma D-dimer levels. These results suggest that plasma

PAGE 14

D-dimer levels on admission provide relevant information for predicting the prognosis ofpatients with ischemic stroke and active cancer.

300

301 Discussion

302 We investigated the prognosis of patients with ischemic stroke and active cancer using data 303 from the SCAN study, a prospective, multicenter, observational study in Japan. Patients with 304 cryptogenic stroke had shorter survival times than those with known etiologies. Distant 305 metastasis, plasma D-dimer levels, and DVT/PE complications at stroke onset were 306 independently associated with mortality after adjusting for potential confounders. Furthermore, 307 plasma D-dimer levels stratified the prognosis of patients with distant metastasis and 308 cryptogenic stroke. The current study suggests that there is a strong relationship between the 309 degree of cancer-associated coagulopathy and the prognosis of patients with ischemic stroke 310 and active cancer.

311 Previous studies have examined the prognosis of patients with ischemic stroke and 312 active cancer. The median survival of these patients, considering all stroke subtypes, ranged 313 from 84 to 109 days [6,7]. In our study, survival time was favorable compared with that in 314 previous reports. The differences in survival among studies could owe to differences in the 315 patients' backgrounds. For example, the proportion of distant metastasis was 66% in the study 316 by Lee et al., and 69% in the study by Navi et al., and 51% in our study. Additionally, 317 cryptogenic stroke, a predictor of poor outcome in patients with ischemic stroke and active 318 cancer, accounted for 72% in the study by Lee et al., and 51% in the study by Navi et al., and 319 48% in our study. Thus, differences in cancer progression and stroke subtypes may influence 320 patients' survival.

In our cohort, patients with cryptogenic stroke had shorter survival times than thosewith known etiologies. This result confirmed the finding from a previous retrospective study

PAGE 15

323 by Navi et al [8]. There are several possible explanations for this finding. First, patients with 324 cryptogenic stroke and active cancer often have cancer-related coagulation abnormalities, 325 resulting in poor outcomes [27]. This is supported by the finding that plasma D-dimer levels 326 were significantly higher in patients with cryptogenic stroke than those with known etiologies 327 [19–21]. Second, distant metastasis was more common in the cryptogenic stroke group, leading 328 to poor prognosis. These backgrounds are associated with high mortality in patients with 329 cryptogenic stroke and active cancer. The current study also demonstrated that patients with 330 cryptogenic stroke had higher serum hsCRP levels than those with known etiologies. 331 Cancer-related chronic inflammation could be associated with cryptogenic stroke and a poor 332 prognosis [28].

333 Cryptogenic stroke has been reported as an independent predictor of mortality in 334 patients with ischemic stroke and active cancer [8]. Other studies have shown plasma d-dimer 335 levels to be also associated with poor prognosis [12,17,18]. Of note, plasma D-dimer levels are 336 reportedly high in patients with cryptogenic stroke and active cancer [19–21]; hence, these 337 findings may reflect underlying coagulation abnormalities. The present study examined the 338 prognostic impact of cryptogenic stroke and plasma D-dimer levels using the multivariate 339 model. Cryptogenic stroke was associated with poor prognosis in univariate analysis but was 340 not significant in multivariate analysis. As mentioned earlier, plasma D-dimer levels were 341 higher in patients with cryptogenic stroke than in those with known etiologies; therefore, the 342 result that cryptogenic stroke was associated with death may be the effect of coagulation 343 abnormalities. Interestingly, among patients with distant metastasis and/or cryptogenic stroke, 344 those with high plasma D-dimer levels had poorer prognosis than those without. This finding 345 supports the notion that the degree of cancer-associated coagulation abnormalities is related to 346 prognosis. In clinical practice, it would be very helpful to use plasma D-dimer levels, in 347 addition to distant metastasis and cryptogenic stoke, to predict the prognosis.

PAGE 16

348 Regarding stroke subtypes, this study classified cryptogenic strokes as patients whose 349 cause could not be confidently identified or had no apparent cause other than malignancy. 350 However, the etiologic classification for patients with cancer-associated hypercoagulability is 351 debatable. This is due to the diversity of cancer-associated stroke phenotypes. For example, if 352 marantic endocarditis, also known as non-bacterial endocarditis, is detected by 353 echocardiography in the cancer population, it would be classified as cardioembolism [24]. If 354 blood tests confirm disseminated intravascular coagulation, it will be categorized as another 355 determined etiology [24]. There are also cases of tumors or air embolisms [29,30]. Meanwhile, 356 even if these causes were not found by screening, they may have gone undetected. If blood tests 357 are incomplete, disseminated intravascular coagulation may not be diagnosed. Therefore, 358 classification for patients with cancer-associated consensus about the etiologic 359 hypercoagulability will be needed.

360 Patients with known etiologies and low D-dimer levels had a better prognosis than 361 those with cryptogenic stroke and severe coagulation abnormalities. This means those with 362 clear traditional stroke etiologies are likely cancer-independent strokes and have a much better 363 prognosis than those with cancer-related strokes. This is presumably because cancer-associated 364 coagulation abnormalities do not affect morbidity and mortality. In other words, patients with 365 active cancer just happened to develop an ischemic stroke, and it is unlikely that 366 cancer-associated hypercoagulability is related to the development of strokes. These results can 367 be a message that clinicians should not deny stroke therapy based on a cancer history, where 368 there is no reason to think cancer caused the stroke.

Hemorrhagic complications are among the most significant concerns in the antithrombotic treatment of ischemic stroke patients with active cancer [31]. In our analysis, antithrombotic therapy significantly reduced recurrent stroke and did not increase major bleeding. Because the SCAN study was observational, the indication for antithrombotic

PAGE 17

medications was left to the attending physician's judgment. Therefore, it is likely that antithrombotic treatment was not given to patients at high risk of bleeding. However, our data prove that antithrombotic medications should be given to patients whose physicians determine they can use antithrombotic drugs. Further studies are needed to determine the pros and cons of antithrombotic therapy in stroke patients with active cancer.

378 The strength of this study resides in its prospective and multicenter design. However, 379 this study had several limitations. First, although we tried to enroll as many patients as possible, 380 we could not obtain consent from all the patients to participate in the study. It is possible that 381 consent was not obtained from patients with advanced cancer and a selection bias could exist. 382 Second, this study did not evaluate whether lowering plasma D-dimer levels with 383 antithrombotic therapy improves prognosis. A recent study has reported that decreasing plasma 384 D-dimer levels with antithrombotic use are associated with prognosis [18]. Third, events, such 385 as stroke recurrence and major bleeding, were collected based on the history provided by the 386 patient or family. Thus, the events may have been underestimated if they were not reported by 387 the participants. Lastly, this study was limited to Japanese patients, so our findings may not 388 generalize to other stroke populations.

In conclusion, this study analyzed the survival of patients with ischemic stroke and active cancer, using data from the SCAN study. The prognosis of ischemic stroke patients with active cancer varies considerably depending on distant metastasis, venous thromboembolism complications, and coagulation abnormalities. Based on this information, clinicians can decide how to treat patients with ischemic stroke and active cancer.

394

PAGE 18

395 Acknowledgements

396 We would like to thank all investigators for their efforts in conducting the SCAN study.

397 Sources of funding

398 This work was supported by JSPS KAKENHI [grant Number: JP15K08915].

399

400 Disclosures

- 401 Dr. Gon: lecturer fees from Eisai, Kyowa Kirin, and Pfizer unrelated to this study.
- 402 Dr. Sakaguchi: lecturer fees from Bayer, Chugai, CSL Behring, Daiichi Sankyo, Eisai, Kyowa
- 403 Kirin, Ono, Otsuka, Takeda, and UCB Japan unrelated to this study.
- 404 Dr. Yamagami: Grants from Bristol-Myers Squibb and lecturer fees from Bayer,
- Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Otsuka, and Stryker unrelated to thisstudy.
- 407 Dr. Todo: lecturer fees from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi
- 408 Sankyo, Kyowa Kirin, Medtronic, Otsuka, Pfizer, Stryker, and Takeda unrelated to this study.
- 409 The authors declare that they have no conflicts of interest.

PAGE 19

410 References

- 411 1. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS,
- 412 DeAngelis LM. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll
- 413 *Cardiol.* 2017;70:926–938.
- 414 2. Mulder FI, Horváth-Puhó E, van Es N, Pedersen L, Büller HR, Bøtker HE, Sørensen HT.
- 415 Arterial Thromboembolism in Cancer Patients: A Danish Population-Based Cohort Study.
- 416 *JACC CardioOncol.* 2021;3:205–218.
- 417 3. Grilz E, Königsbrügge O, Posch F, Schmidinger M, Pirker R, Lang IM, Pabinger I, Ay C.
- 418 Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients
 419 with cancer. *Haematologica*. 2018;103:1549–1556.
- 420 4. Gon Y, Sasaki T, Kawano T, Okazaki S, Todo K, Takeda T, Matsumura Y, Mochizuki H.
- 421 Impact of stroke on survival in patients with cancer. *Thromb Res.* 2023;222:109–112.
- 422 5. Gon Y, Zha L, Sasaki T, Morishima T, Ohno Y, Mochizuki H, Sobue T, Miyashiro I. Stroke
 423 mortality in cancer survivors: A population-based study in Japan. *Thromb Res.*424 2023;222:140–148.
- 425 6. Lee MJ, Chung JW, Ahn MJ, Kim S, Seok JM, Jang HM, Kim GM, Chung CS, Lee KH,
- Bang OY. Hypercoagulability and Mortality of Patients with Stroke and Active Cancer:
 The OASIS-CANCER Study. *J Stroke*. 2017;19:77–87.
- 7. Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, Iadecola C, Elkind MS,
 DeAngelis LM. Recurrent thromboembolic events after ischemic stroke in patients with
 cancer. *Neurology*. 2014;83:26–33.
- Shin YW, Lee ST, Jung KH, Kim DY, Park CK, Kim TM, Choi SH, Chu K, Lee SK.
 Predictors of survival for patients with cancer after cryptogenic stroke. *J Neurooncol*.
 2016;128:277–284.
- 434 9. Zhang YY, Chan DK, Cordato D, Shen Q, Sheng AZ. Stroke risk factor, pattern and

435		outcome in patients with cancer. Acta Neurol Scand. 2006;114:378-383.							
436	10.	Sorgun MH, Kuzu M, Ozer IS, Yilmaz V, Ulukan C, Cotur Levent H, Tezcan S, Rzayev S,							
437		Rawandi A, Bakırarar B, et al. Risk Factors, Biomarkers, Etiology, Outcome and							
438		Prognosis of Ischemic Stroke in Cancer Patients. Asian Pac J Cancer Prev. 2018;19:649-							
439		653.							
440	11.	Seystahl K, Hug A, Weber SJ, Kapitza S, Gramatzki D, Wanner M, Katan M, Luft AR,							
441		Rohrmann S, Wegener S, et al. Cancer is associated with inferior outcome in patients with							
442		ischemic stroke. J Neurol. 2021;268:4190-4202.							
443	12.	Gon Y, Kabata D, Kawano T, Kanki H, Todo K, Sasaki T, Shintani A, Mochizuki H.							
444		Hematological Abnormalities and Malnutrition Mediate Pathway between Cancer and							
445		Outcomes in Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2020;29:104943.							
446	13.	13. Verschoof MA, Groot AE, de Bruijn SFTM, Roozenbeek B, van der Worp HB, Dippel							
447		DWJ, Emmer BJ, Roosendaal SD, Majoie CBLM, Roos YBWEM, et al. Clinical Outcome							
448		After Endovascular Treatment in Patients With Active Cancer and Ischemic Stroke: A MR							
449		CLEAN Registry Substudy. Neurology. 2022;98:e993-e1001.							
450	14.	Tanimura J, Yamamoto T, Hashimoto T. Clinical features and prognostic factors in							
451		patients with cancer-associated multiple ischemic stroke: A retrospective observational							
452		study. J Stroke Cerebrovasc Dis. 2022; 31;106813.							
453		https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106813							
454	15.	Salazar-Camelo RA, Moreno-Vargas EA, Cardona AF, Bayona-Ortiz HF. Ischemic stroke:							
455		A paradoxical manifestation of cancer. Crit Rev Oncol Hematol. 2021;157:103181.							
456	16.	Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, Iadecola C, Elkind MS,							
457		DeAngelis LM. Cryptogenic subtype predicts reduced survival among cancer patients with							
458		ischemic stroke. 2014;45:2292–2297.							
459	17.	Nam KW, Kim CK, Kim TJ, An SJ, Oh K, Mo H, Kang MK, Han MK, Demchuk AM, Ko							

SB, et al. Predictors of 30-day mortality and the risk of recurrent systemic

thromboembolism in cancer patients suffering acute ischemic stroke. PLoS One.

18. Nakajima S, Kawano H, Yamashiro K, Tanaka R, Kameda T, Kurita N, Hira K, Miyamoto

460

461

462

463

2017;12:e0172793.

PAGE 21

464		N, Ueno Y, Watanabe M, et al. Post-Treatment Plasma D-Dimer Levels Are Associated
465		With Short-Term Outcomes in Patients With Cancer-Associated Stroke. Front Neurol.
466		2022;13:868137.
467	19.	Gon Y, Okazaki S, Terasaki Y, Sasaki T, Yoshimine T, Sakaguchi M, Mochizuki H.
468		Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol.
469		2016;3:280–287.
470	20.	Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, Kablau M, Hennerici MG,
471		Fatar M. Stroke and cancer: the importance of cancer-associated hypercoagulation as a
472		possible stroke etiology. Stroke. 2012;43:3029–3034.
473	21.	Kim SG, Hong JM, Kim HY, Lee J, Chung PW, Park KY, Kim GM, Lee KH, Chung CS,
474		Bang OY. Ischemic stroke in cancer patients with and without conventional mechanisms: a
475		multicenter study in Korea. Stroke. 2010;41:798-801.
476	22.	Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, Zielinski C, Pabinger I.
477		High D-dimer levels are associated with poor prognosis in cancer patients. <i>Haematologica</i> .
478		2012;97:1158–64.
479	23.	Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prové A,
480		Lemmens J, Vermeulen P. Plasma fibrin D-dimer levels correlate with tumour volume,
481		progression rate and survival in patients with metastatic breast cancer. Br J Cancer.
482		2002;86:389–95.
483	24.	Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd.
484		Classification of subtypes of acute ischemic stroke. Definitions for use in a multicenter

PAGE 22

	485	clinical trial. TO	AST. Trial of Org	g 10172 in Acu	te Stroke Treatment	. Stroke. 1993;24:35-
--	-----	--------------------	-------------------	----------------	---------------------	-----------------------

- 486 41.
- 487 25. Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical
 488 prediction modelling. *Fam Med Community Health.* 2020;8(1):e000262.
- 489 26. Fine JP, Gray RJ. A proportional hazard model for the subdistribution of a competing risk.
- 490 *J Am Stat Assoc*. 1999;94:496–509.
- 491 27. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy:

492 pathogenesis and current debate. *Neoplasia*. 2002;4:465–73.

- 493 28. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420:860–867.
- 494 29. Takasugi J, Sakaguchi M, Oyama N, Gon Y, Terasaki Y, Sasaki T, Nakahara S, Ohshima K,
- 495 Hori Y, Morii E, Mochizuki H. Recurrent Stroke Due to Metastatic Pulmonary Tumor
- 496 Emboli as an Important Clinical Entity. *J Stroke Cerebrovasc Dis*. 2017;26:e108–e110.
- 497 30. Miyamoto S, Mashimo Y, Horimatsu T, Ezoe Y, Morita S, Muto M, Chiba T. Cerebral air
 498 embolism caused by chemoradiotherapy for esophageal cancer. J Clin Oncol.
- 499 2012;30:e237–8.
- 500 31. Navi BB, Kasner SE, Elkind MSV, Cushman M, Bang OY, DeAngelis LM. Cancer and
- 501 Embolic Stroke of Undetermined Source. *Stroke*. 2021;52:1121–1130.
- 502

PAGE 23

503 Tables

504 **Table 1.** Index of cancer

Site of cancer	Total ($N = 135$)	Distant metastasis ($N = 69$)
Lung	16% (22)	68% (15)
Colorectal	14% (19)	47% (9)
Pancreas	13% (18)	94% (17)
Prostate	9% (12)	33% (4)
Gastric	8% (11)	45% (5)
Breast	7% (10)	30% (3)
Lip, oral, and pharynx	7% (9)	67% (6)
Esophagus	4% (6)	17% (1)
Bladder	4% (6)	33% (2)
Liver	4% (5)	20% (1)
Gallbladder	3% (4)	75% (3)
Malignant lymphoma	2% (3)	67% (2)
Other*	7% (10)	14% (1) [†]

505 NA, not assigned. Data are presented as % (n).

* Include uterus (n = 2), myeloproliferative disorder (n = 2), ovarian (n = 1), renal (n = 1),

507 thyroid (n = 1), leukemia (n = 1), vulvar (n = 1), and soft tissue malignancies (n = 1).

[†] The percentage of the seven solid tumors is shown.

509

510	Table 2. Characteristi	es of the	e patients	according to	stroke subtypes

Variables	Total (N =	Cryptogenic	Known etiologies	P
	135)	stroke (N =	(<i>N</i> = 70)	value‡
		65)		
Age, years, median (IQR)	75 (69–81)	75 (68–82)	75 (70–80)	0.87
Women	39% (52)	48% (31)	30% (21)	0.035
Hypertension	62% (83)	52% (34)	70% (49)	0.035
Dyslipidemia	34% (46)	31% (20)	37% (26)	0.43
Diabetes mellitus	22% (30)	22% (14)	23% (16)	0.85
Smoking	19% (25)	15% (10)	21% (15)	0.37
Atrial fibrillation	22% (30)	5% (3)	37% (26)	< 0.001
Past stroke	19% (25)	11% (7)	26% (18)	0.026
Time from symptom onset	0 (0–2)	0 (0–2)	0 (0-1)	0.39
to admission, days, median				
(IQR)				
Pre-stroke	30% (41)	25% (16)	36% (25)	0.16
Antithrombotics use				
Antiplatelets	21% (28)	18% (12)	23% (16)	0.24
Anticoagulants	13% (17)	11% (7)	14% (10)	0.54
Stroke subtypes				
SVO	8% (11)			
LAA	15% (20)			
CES	22% (29)			
Other	7% (10)			
	1	1	l	L

Cryptogenic	48% (65)			
NIHSS, median (IQR)	4 (2–10)	5 (2-10)	3 (2–10)	0.47
Pre-mRS, median (IQR)	0 (0–2)	1 (0-3)	0 (0-2)	0.039
Infarcts in multivascular	45% (61)	64% (41)	29% (20)	< 0.001
territories				
DVT/PE Complications at	7% (10)	14% (9)	1%(1)	0.006
stroke onset				
Rt-PA	7% (9)	8% (5)	6% (4)	0.65
МТ	10% (14)	8% (5)	13% (9)	0.33
Distant metastasis	51% (69)	65% (42)	39% (27)	0.002
Adenocarcinoma [*]	56% (55)	59% (27)	53% (28)	0.56
Pre-stroke Cancer	76% (103)	67% (43)	86% (60)	0.011
treatment				
Cancer surgery	28% (38)	17% (11)	39% (27)	0.006
Chemotherapy	47% (64)	52% (33)	44% (31)	0.40
Radiotherapy	11% (15)	9% (6)	13% (9)	0.52
Antithrombotics after	82% (111)	85% (55)	80% (56)	0.48
stroke onset				
Antiplatelets	32% (43)	17% (11)	45% (32)	< 0.001
Anticoagulants	68% (92)	77% (50)	60% (42)	0.11
Recurrent stroke	10% (13)	12% (8)	7% (5)	0.31
Major bleeding	7% (10)	11% (7)	4% (3)	0.15
D-dimer, µg/mL, median	3.65 (1.41–	10.35 (3.59–	1.76 (0.83–3.73)	< 0.001
(IQR) [†]	11.72)	22.38)		

PAGE 26

High sensitivity C-reactive	1.06	(0.18–	2.50	(0.44–	0.44 (0.12–2.56)	< 0.001
protein, mg/dL, median	3.95)		5.97)			
(IQR)						

511 Data are presented as % (N) or median and interquartile ranges (IQR).

^{*} Pathological findings were not available for 36 patients (19 with cryptogenic stroke and 17

513 with known etiologies); therefore, the results were analyzed for 99 patients.

- [†]Plasma D-dimer levels were not available in three patients (one with cryptogenic stroke and
- 515 two with known etiologies).

[‡]Comparisons between the patients with cryptogenic stroke and known etiologies.

517 IQR, interquartile ranges; SVO, small vessel occlusion; LAA, large artery atherosclerosis; CES,

518 cardioembolism; NIHSS, National Institute of Health Stroke Scale; mRS, modified Rankin

519 Scale; DVT, deep venous thrombosis; PE, pulmonary embolism; Rt-PA, Recombinant tissue

520 plasminogen activator; MT, mechanical thrombectomy.

521

PAGE 27

522 Table 3. Hazard ratios for mortality using Cox regression model (univariate and

523 multivariate)

	Univariate	Multivariate	
		Model 1	Model 2
Variables	HR (95% CI)	HR (95% CI)	HR (95% CI)
Age, per 1-year	1.00 (0.98–1.02)	1.00 (0.98–1.03)	-
increase			
Women	0.93 (0.56–1.57)	0.81 (0.40–1.64)	-
Hypertension	0.49 (0.30–0.81) [†]	0.65 (0.30–1.43)	0.57 (0.31–1.04)
Dyslipidemia	0.75 (0.44–1.29)	0.68 (0.31–1.49)	_
Diabetes mellitus	1.29 (0.73–2.28)	1.34 (0.67–2.70)	-
Atrial fibrillation	$0.45~(0.21-0.94)^{\dagger}$	0.62 (0.23–1.70)	-
Past stroke	0.46 (0.21–1.01)	0.60 (0.23–1.52)	-
Pre-stroke	0.67 (0.37–1.19)	0.56 (0.27–1.16)	0.55 (0.28–1.06)
antithrombotic use			
Cryptogenic stroke	3.11 (1.82–5.32) [‡]	0.72 (0.32–1.62)	0.87 (0.44–1.68)
NIHSS, per 1-score	1.03 (1.00–1.06) [†]	1.01 (0.96–1.07)	-
increase			
Pre-mRS ≤2	0.72 (0.40–1.23)	0.83 (0.41–1.70)	-
DVT/PE	4.82 (2.33–9.98) [‡]	3.16 (1.26–7.95)*	3.16 (1.45–6.85) [†]
Complications			
Distant metastasis	5.50 (3.02–10.00) [‡]	3.22 (1.54–6.74)*	3.24 (1.56–6.73) [†]
Pre-stroke Cancer	0.50 (0.29–0.86)*	0.51 (0.22–1.18)	0.57 (0.25–1.30)
treatment			
Recurrent Stroke	3.31 (1.69–6.48) [‡]	1.94 (0.52–7.22)	1.86 (0.53–6.54)
Major bleeding	2.33 (0.93–5.81)	1.60 (0.27–9.65)	-
Plasma D-dimer			
levels			
<25 th	(Ref)	(Ref)	(Ref)
$\geq 25^{\text{th}} \text{ and } < 50^{\text{th}}$	4.24 (1.39–12.90)*	1.72 (0.44–6.63)	2.12 (0.57–7.83)
\geq 50 th and <75 th	7.56 (2.59–22.10) [‡]	3.31 (0.89–12.37)	3.55 (1.07–11.75)*
≥75 th	11.22 (3.86–32.60) [‡]	3.16 (0.79–12.58)	3.90 (1.17–12.99)*

- 524 Model 1 was developed using the forced entry method for all potential confounders. In Model
- 525 2, cryptogenic stroke was forced in and the other factors were selected using a stepwise
- 526 method with Akaike's information criterion.
- 527 * P < 0.05; [†] P < 0.01; [‡] P < 0.001
- 528 HR, hazard ratio; CI, confidence interval; NIHSS, National Institute of Health Stroke Scale;
- 529 mRS, modified Rankin Scale; DVT, deep venous thrombosis; PE, pulmonary embolism

PAGE 29

530	Figure 1	Legends
-----	-----------------	---------

531 Figure 1. Kaplan-Meier survival curves by stroke mechanism

532

- 533 Figure 2. Cumulative incidence of recurrent stroke by antithrombotic agents use
- 534 HR, hazard ratio; CI, confidence interval

535

- 536 Figure 3. Cumulative incidence of major bleeding by antithrombotic agent use
- 537 HR, hazard ratio; CI, confidence interval

538

539 Figure 4. The distribution of plasma D-dimer levels by (A) distant metastasis and (B) stroke
540 subtypes

- 541 (A) The median plasma D-dimer levels for patients with metastasis was 8.51 µg/mL
- 542 (interquartile range of 2.20–20.72 μg/mL), and that for patients with non-metastasis was 1.91
- 543 (interquartile range of 0.79–6.71 μg/mL). (B) The median plasma D-dimer levels for patients
- 544 with cryptogenic stroke was 10.35 μg/mL (interquartile range of 3.59–22.38 μg/mL), and that
- for patients with known etiologies was 1.76 (interquartile range of $0.83-3.73 \mu g/mL$).

546

547 Figure 5. Kaplan-Meier survival curves stratified by (A) distant metastasis and (B) stroke
548 subtype based on quartiles of plasma D-dimer levels

549 We analyzed the survival rates of 132 patients since the plasma D-dimer levels on admission

were not available for three patients. (A) The median plasma D-dimer levels were $1.91 \,\mu g/mL$

- for the group with non-metastasis and $8.51 \,\mu\text{g/mL}$ for the group with metastasis; therefore, we
- 552 divided the patients into four groups based on distant metastasis status and median plasma
- 553 D-dimer levels. (B) The median plasma D-dimer levels were 1.76 µg/mL for the known
- etiologies group and 10.35 μ g/mL for the cryptogenic stroke group; therefore, we divided the

- 555 patients into four groups based on stroke subtype and median plasma D-dimer levels. Plasma
- 556 D-dimer levels provide additional prognostic information for patients with distant metastasis
- 557 and stroke subtype.
- 558
- 559











- Group 2: Metastasis (−) and D-dimer ≥1.91 µg/mL
- Group 3: Metastasis (+) and D-dimer <8.51 μg/mL
- Group 4: Metastasis (+) and D-dimer ≥8.51 µg/mL



Group 1: Known etiologies and D-dimer <1.76 μg/mL

- Group 2: Known etiologies and D-dimer ≥1.76 µg/mL
- Group 3: Cryptogenic stroke and D-dimer <10.35 μg/mL
- Group 4: Cryptogenic stroke and D-dimer ≥10.35 μg/mL